Frontlight ResearchEarly access
Taking people in FrancePhase 1
Tests etanercept with repeated ultrasound in people with Alzheimer's disease
Checks the safety of etanercept given with repeated ultrasound scans in adults with Alzheimer's.
Key facts
- Who runs it
- Hopital Fondation Adolphe De Rothschild
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Evaluation of the safety of a strategy combining etanercept administration with repeated contrast ultrasound in patients with Alzheimer's disease: a phase I study
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 5 people, planned
- Started
- 16 Apr 2025
- Expected to end
- 2 Oct 2027
- Type of study
- Interventional
- Record updated
- 21 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Alzheimer's disease to test the safety of etanercept given together with repeated contrast ultrasound.
- Age
- 18 years and older
- Sex
- All sexes can join.
This trial is currently available in France.
- Hopital Fondation Adolphe de RothschildParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests etanercept with repeated ultrasound in people with Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 21 May 2026